Dyadic's Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing Standards

Receives Notice of Continuing Failure to Satisfy Certain Amex Continued Listing

Fla - August 28, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today

that it has received a second notice from The American Stock Exchange (the

"Amex") indicating that the Company continues to be in violation of the Amex

continued listing standards specified in Sections 134 and 1101 of the Amex

Company Guide because the Company has yet to file with the Securities and

Exchange Commission ("SEC") its Form 10-QSB for the quarters ended March 31,

2007, and June 30, 2007.

Company's plan of compliance, previously filed with the Amex on June 18, 2007,

in connection with its delinquent Form 10-QSB for the quarter ended March 31,

2007 and accepted by the Amex on July 2, 2007, is still in effect, as it

demonstrates the Company's ability to regain compliance with its filing

obligations by the end of the plan period, which has been determined to be

later than November 16, 2007. Therefore, the Company is not required to file

with the Amex a new plan of compliance. However, if the Company is not in

compliance with all of the Amex continued listing standards by the end of the

plan period or does not make progress consistent with the plan prior to the

of the plan period, the Amex will initiate delisting proceedings against the

Company as appropriate pursuant to Section 1009 of the Company Guide.

Company will not be deemed to have regained compliance with the Amex continued

listing standards, and trading in the Company's common stock will not resume

the Amex, until the Company is current with the filing of its SEC quarterly

reports and other SEC periodic reports, which it anticipates will occur by

end of the plan period.

International, Inc. is a biotechnology company that uses its patented and

proprietary technologies to conduct research and development activities for

discovery, development, and manufacture of products and enabling solutions

the bioenergy, industrial enzyme and pharmaceutical industries.

Statement for Forward-Looking Statements

statements contained in this press release are "forward-looking statements."

These forward-looking statements involve risks and uncertainties that could

cause our actual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by

such forward-looking statements. For a discussion of these risks and

uncertainties, please see our filings from time to time with the Securities

Exchange Commission, which are available free of charge on the SEC's web site

http://www.sec.gov, including our Annual Report on Form 10-KSB for the year

ended December 31, 2006, and our subsequent filings with the SEC. Except as

required by law, we expressly disclaim any intent or obligation to update any

forward-looking statements.

(Sasha) Bondar, 561-743-8333

Berkman, 310-826-5051